LA JOLLA, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Lesley Probert, Ph.D., Head of Immunology Department at the  Hellenic Pasteur Institute in Athens, Greece, will be presenting a poster about new data on the company’s neurodegenerative disease drug candidate XPro1595 at The European Conference on Neuroinflammation on April 8 and 9.

The poster presentation, titled “Selective inhibition of soluble TNF promotes macrophage phagocytosis of myelin debris and remyelination of demyelinated lesions”, is a follow up study of Dr. Probert’s earlier work demonstrating that XPro1595 promotes remyelination in animal models of Multiple Sclerosis. The current study sheds some light onto how XPro1595 does this. Dr. Probert found that XPro1595 may promotes remyelination by increasing the presence of immune cells that remove damaged myelin. “Clearing out the dead myelin is a key trigger for remyelination. We believe that inflammation, and particularly soluble tumor necrosis factor (the target of XPro1595), changes the function of macrophages, from cells that usually clear dead myelin, to inflammatory cells that perpetuate disease pathology,” says Dr. Probert. 

Dr. Probert is one of the world’s leading experts on tumor necrosis factor (TNF) biology in the brain as it relates to myelin – the insulation around neurons that are key to making them work and the pathology associated with Multiple Sclerosis.

XPro1595 has been tested in multiple animal models of Multiple Sclerosis by a number of research groups in the US and Europe. “The work done by Dr. Probert and others with XPro1595 in the Multiple Sclerosis models is very impressive,” says Dr. CJ Barnum, the Director of Neuroscience for INmune Bio. “ We look forward to seeing how their work advances and what this might mean for patients suffering from MS.”

The European Conference on Neuroinflammation – Basic and Clinical Concepts in association with The Oxford Centre for Neuroinflammation is the first in a series of annual events that will facilitate the investigative and analytical discussion of a range of neurodegenerative diseases.

About XPro1595
XPro2595 is a novel biologic DN-TNF therapy that neutralizes soluble TNF without affecting trans-membrane TNF or TNF receptors.  XPro1595 is entering a biomarker directed Phase I clinical trial in patients with mild-to-moderate Alzheimer’s disease who have biomarkers of neuroinflammation to determine if neutralizing soluble TNF can decrease those biomarkers neuroinflammation There can be no assurance that XPro1595 or any of the company’s other products will be granted approvals or that the data presented in the Poster Presentation will result in successful clinical trials.

About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

Information about Forward-Looking Statements
Statements in this press release relating to our drug candidates and our ability to optimize our opportunities for growth and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. 

This release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. For a more detailed description of the risk factors and uncertainties affecting the Company please refer to the Company’s recent Securities and change Commission filings, which are available at https://www.sec.gov/cgi-bin/browse-edgar?company=inmune&owner=exclude&action=getcompany.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:
Antenna Group
Sharon Golubchik
(201) 465-8008
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact: 
KCSA Strategic Communications
Valter Pinto / Scott Eckstein 
PH: (212) 896-1254 / (212) 896-1210
This email address is being protected from spambots. You need JavaScript enabled to view it.

Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST